Program
INE963
Also written as “INE 963”.
In Novartis's pipeline, Plasmodium falciparum inhibitor
. Its studies are mostly in Malaria, Falciparum, led by Novartis.
Furthest: phase 2, since Feb 17, 20234 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 41 open or running | phase 2since Feb 17, 2023 | May 12, 2021 | none ahead |
- Named in Novartis’s own pipeline as
INE963
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 12, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT04896632 · 64 enrolled · United Kingdom
- Feb 17, 2023Phase 2 study in MalariaNCT05750628 · 327 planned · Burkina Faso, Côte d’Ivoire, Gabon and more
- Nov 14, 2025Phase 2 study in Malaria, FalciparumNCT07235020 · 52 enrolled · Burkina Faso, Côte d’Ivoire, Gabon and more
- Sep 4, 2026Phase 2 study in Malaria, FalciparumNCT07811882 · 95 enrolled · Burkina Faso, Côte d’Ivoire, Gabon and more
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Plasmodium falciparum inhibitor”the company's pipeline, read by Claude · source
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07811882Malaria, Falciparum · Burkina Faso, Côte d’Ivoire, Gabon and more | 2 | Completed | Jun 17, 2026 | 95 |
| NCT07235020Malaria, Falciparum · Burkina Faso, Côte d’Ivoire, Gabon and more | 2 | Completed | Jan 30, 2025 | 52 |
| NCT05750628Malaria · Burkina Faso, Côte d’Ivoire, Gabon and more | 2 | Recruiting | Jun 9, 2026 | 327 |
| NCT04896632Healthy Volunteers · United Kingdom | 1 | Terminated | Nov 24, 2022 | 64 |
How it is read
Names in the registry
- “INE963”, 3 entries
- “INE 963”, 1 entry
Conditions, from the studies’ own filings
- Malaria, Falciparum, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.